Text Size A A A

Research & Development

Tell a Friend Print Home » Research

Sun Pharma’s core strength lies in our ability to excel in developing technologically complex products through focused teams in formulations, process chemistry and analytical development following a strategy of development of difficult to mimic generics in defined specialty areas.

The company’s research commitment usually is between 7-8% of revenue and more than Rs. 20 billion has been spent for generic research since 1993. Every year, Sun typically brings about 30 new products to the Indian market, scales up 25 API including drug master files for US and Europe and develops and files for more than 30 ANDAs for the US. As of June 2012, 266 products have been approved by the USFDA for sale in the United States and 135 filings await approval.

Sun Pharma, along with its subsidiaries, has four state-of-the-art R&D centers across the world with more than 800 scientists employed.

 

Research Centers

Vadodara, India

Vadodara, India

  Mumbai, India

Mumbai, India

  Haifa, Israel

Haifa, Israel (Taro)

 
Brampton, Canada

Brampton, Canada (Taro)

  New York, USA

New York, USA (Taro)